News and Trends 4 Jan 2023 Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation Infex Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to MET-X, the company’s broad spectrum metallo-beta-lactamase (MBL) inhibitor. Infex Therapeutics’ MET-X is a resistance bypass treatment that targets Gram-negative Enterobacterales. These pathogens produce MBL enzymes to deactivate beta-lactam antibiotics and evade antibiotic clearance of […] January 4, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2023 Aditxt forms Adimune to focus on immune modulation therapies Aditxt, Inc., a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has formed a U.S.-based subsidiary Adimune, Inc. The plan is to submit a clinical trial application (CTA) for its immunotherapeutic technology drug candidate, ADI-100 (ADI). The CTA will request approval for Adimune to conduct the […] January 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Janssen looks for talquetamab marketing approval The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for approval of talquetamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody targeting both GPRC5D, a novel drug […] January 3, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Legend Biotech new drug application approved in China Legend Biotech Corporation has announced that China’s National Medical Products Administration (NMPA) has formally accepted its new drug application (NDA) for ciltacabtagene autoleucel (cilta-cel). This submission is based on data from the confirmatory phase 2 clinical study CARTIFAN-1, conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or […] January 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Newron announces interim results from treatment-resistant schizophrenia trial Newron Pharmaceuticals S.p.A. has announced what it says are “very compelling new results” from the first 100 enrolled patients to have reached the six-month timepoint in its international study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS), who were not responding to their current […] January 3, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial Sensorion has announced that the first patient has been enrolled in its phase 2a proof of concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, […] January 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Blacksmith Medicines merging with Forge Therapeutics Blacksmith Medicines, Inc., and Forge Therapeutics have signed a definitive merger agreement. This will create a biopharma company dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes. The initial focus will be on oncology and infection. “We are excited to unveil the merger of Blacksmith and Forge, which we believe […] January 3, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jan 2023 Watch: Addressing IP with Starting Bloch Starting Bloch is a French-headquartered company helping companies navigate the world of IP and patents. The company’s Patman platform was developed to assist companies with patents, licenses and trademarks. The company also assists companies addressing fundraising, as well as helping with management and tech transfer. Patman gives companies a calendar of events to address issues […] January 1, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jan 2023 Watch: Roquefort Therapeutics at BioFIT Roquefort Therapeutics is a biotech company developing first-in-class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth […] January 1, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Dec 2022 Watch: Zoetis looks for partnerships at BioFIT Animal health company, Zoetis, has a pipeline of medicines, vaccines, diagnostics and technologies for livestock and pets. Active in more than 100 countries, Zoetis generated revenue of $7.8 billion in 2021, and has approximately 12,100 employees. The company recently announced a collaboration with the partners of the Pastoral Greenhouse Gas Research Consortium, and the New […] December 29, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Watch: Eva Hoffmann talks about genetics and fertility Eva R. Hoffmann is the Professor in Molecular Genetics at the Department of Cellular and Molecular Medicine at the University of Copenhagen in Denmark. She is involved in the Molecular Aging Program, Medical Genetics Program and the Centre for Chromosome Stability. Hoffmann’s laboratory investigates the role of the DNA damage response and cell cycle proteins in […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Watch: Something to SmiLe about in southern Sweden SmiLe Incubator is a life science business incubator based in Medicon Village in Lund, Sweden. SmiLe helps entrepreneurs commercialize their ideas. There are currently 30 companies in the SmiLe Incubator that, together with alumni companies, have attracted more than €664 million ($705 million) in venture capital since 2014. SmiLe offers business coaching, a broad international […] December 23, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email